NCT04538352 - Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

November 1, 2023

Conditions

Type 2 Diabetes

Interventions

DRUG

Semaglutide

Medication for type 2 diabetes management

DRUG

Insulin Degludec

Medication for type 2 diabetes management

DRUG

Insulin aspart

Medication for type 2 diabetes management (rapid-acting)

Trial Locations (1)

Cleveland Clinic, Cleveland